Abstract

Variants of undetermined significance (VUS) in BRCA1 and BRCA2 present major challenges in clinical cancer genetics and personalized risk assessment. In this work, we functionalize and characterize a panel of BRCA repair pathway variants using cellular DNA repair assays and homologous recombination fidelity measures. Our findings provide biochemical and functional classifications that help distinguish pathogenic alterations from benign polymorphisms.